The Ledger

Eli Lilly is paying a Chinese biotech up to $3.35 billion for cancer and autoimmune drug targets that do not exist as products yet, and 97 percent of that number depends on trials that have not started. InnoCare Pharma and Eli Lilly announced September 24, 2026 a strategic research collaboration and license agreement under which InnoCare will discover and advance compounds against up to five undisclosed targets, with Lilly taking over development and commercialization. InnoCare receives up to $100 million in upfront and near-term payments now, plus up to approximately $3.25 billion tied to development and commercial milestones that have not been hit, plus tiered single-digit royalties on any eventual sales. Neither company disclosed the specific indications or targets. The deal illustrates a pattern in big pharma’s China-sourced licensing wave: headline values are overwhelmingly contingent, with cash certainty limited to a small upfront slice. Confidence: High. This run reviewed InnoCare’s own announcement directly. Sources: InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly, GlobeNewswire, Lilly’s $3.35 Billion InnoCare Deal Is 97% Milestones, BioPharm International.

A federal watchdog says two of the country’s biggest Medicare Advantage insurers overbilled the government almost $180 million by claiming patients were sicker than their own medical records show, and both are refusing to pay a cent of it back. The Department of Health and Human Services Office of Inspector General (HHS OIG) completed compliance audits, published this month, finding that HumanaChoice and UnitedHealthcare of Wisconsin frequently submitted diagnosis codes to the Centers for Medicare and Medicaid Services (CMS) that were not supported by medical documentation. For HumanaChoice, 178 of 220 sampled enrollee-years lacked supporting records, extrapolating to roughly $130.9 million in overpayments; for UnitedHealthcare of Wisconsin, 183 of 250 sampled enrollee-years were unsupported, extrapolating to at least $46.9 million. OIG recommended both insurers refund CMS and tighten compliance; both companies called the audit methodology flawed and said they do not plan to repay. The findings land alongside Sen. Chuck Grassley’s ongoing Medicare Advantage risk-adjustment oversight and a Department of Justice inquiry into UnitedHealth’s billing practices, keeping regulatory pressure on the industry’s highest-margin revenue lever. Confidence: High. This run reviewed HHS OIG’s own audit reports directly. Sources: Medicare Advantage Compliance Audit of Specific Diagnosis Codes That HumanaChoice (Contract H5216) Submitted to CMS, HHS OIG, Medicare Advantage Compliance Audit of Specific Diagnosis Codes That UnitedHealthcare of Wisconsin, Inc. (Contract H5253) Submitted to CMS, HHS OIG, Federal watchdog accuses Humana, UnitedHealthcare Medicare Advantage plans of upcoding, Healthcare Dive.

UnitedHealth, CVS’s Aetna and Kaiser Permanente are fighting a Medicare proposal that would cut off the outsourced vendors running their own remote patient monitoring programs, while Humana and Blue Cross plans are backing the very rule that would ban that business model. CMS’s Calendar Year 2027 Physician Fee Schedule proposed rule, published in the Federal Register July 16, 2026, would from January 1, 2027 pay for remote physiologic and remote therapeutic monitoring only when the clinical staff furnishing the service are direct employees of the billing practice, effectively banning the third-party contractor model that has grown quickly under current codes. The public comment period closed September 14; UnitedHealth Group, CVS Health and Kaiser Permanente all wrote CMS opposing the outsourcing ban, with CVS arguing Medicare should set vendor standards instead and Kaiser warning it would disproportionately hit integrated delivery systems, while Humana and Blue Cross plans support the restriction. CMS says the proposal responds to compliance concerns raised in recent OIG reports on remote monitoring billing. If finalized, digital health companies that supply outsourced remote monitoring staff to physician practices face a potential reimbursement cliff at the start of 2027. Confidence: High on the rule and the industry split; Medium on final outcome and timing, since the rule remains proposed. Sources: Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule, Federal Register, UnitedHealth, CVS push back on Medicare plan to curb remote patient monitoring, STAT, CMS’ proposed remote patient monitoring ban, explained, Becker’s Hospital Review.

Ascension just agreed to sell its stake in a profitable Arizona Medicaid insurer to Aetna, the latest sign the nonprofit hospital giant would rather collect a check than keep carrying insurance risk. Ascension is exiting its ownership position in Mercy Care, a Medicaid managed care plan it has co-owned with CommonSpirit’s Dignity Health since Mercy Care’s founding in 1985, selling its stake to CVS Health-owned Aetna, which has run the plan’s day-to-day operations since 2002. Mercy Care reported $34 million in income last year and serves a high-margin population that includes dual-eligible members. Terms were not disclosed, the deal has not set a closing date, and it remains pending regulatory approval. The sale continues a pattern of divestitures for Ascension as it reorients its portfolio following years of financial losses and the fallout from its 2024 cyberattack. Confidence: Medium-High. This run relied on trade press reporting of the companies’ plans; no joint press release from Ascension or CVS Health was located directly. Sources: Ascension sells ownership in Arizona Medicaid plan to Aetna, Healthcare Dive, Ascension to sell share of managed care health plan to Aetna, Becker’s Hospital Review.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
InnoCare Pharma (research collaboration, up to 5 drug targets)	Eli Lilly	Pharma R&D licensing, oncology and autoimmune disease	Up to $3.35 billion ($100 million upfront/near-term plus up to $3.25 billion in milestones); announced September 24, 2026	InnoCare press release, GlobeNewswire
Mercy Care (Arizona Medicaid managed care plan, Ascension’s ownership stake)	Aetna (CVS Health)	Medicaid managed care	Undisclosed; pending regulatory approval, no closing date set	Healthcare Dive
ADARx Pharmaceuticals (IPO, Nasdaq: ADRX)	Public markets; AbbVie concurrent private placement for a 4.9% stake	Biotech, siRNA therapeutics	$446.3 million raised, priced at $17 per share (high end of range) September 24, 2026; offering expected to close September 28	Adarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO, Bloomberg
Independence Health System (5 hospitals, western Pennsylvania)	WVU Health System (WVU Medicine)	Nonprofit hospital affiliation	$800 million in planned investment over 5 years; deal signed June 2026, close expected late September or early October 2026; still not confirmed closed as of this run	WVU Medicine definitive agreement, WVU Medicine newsroom

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours. The MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in active discovery with no new development since this newsletter’s September 26 coverage. A frontier check on the nonprofit capital and municipal bond market (branch B-1) and the plasma collection industry (branch SC-7b) found no dated transaction inside this run’s freshness window; a spot check of senior housing real estate turned up American Healthcare REIT’s $696 million purchase of eight LCB Senior Living communities, but that deal was announced September 3 and falls outside this run’s window. An open-ended scan surfaced Renaissance Capital’s IPO Center as a useful recurring tracker for healthcare and biotech IPO pricing and terms, used this run to confirm the ADARx Pharmaceuticals offering; it is added to this newsletter’s source stack.